Journal article icon

Journal article

Bicyclic boronates as potent inhibitors of AmpC, the class C β-lactamase from escherichia coli

Abstract:

Resistance to β-lactam antibacterials, importantly via production of β-lactamases, threatens their widespread use. Bicyclic boronates show promise as clinically useful, dual-action inhibitors of both serine- (SBL) and metallo- (MBL) β-lactamases. In combination with cefepime, the bicyclic boronate taniborbactam is in phase 3 clinical trials for treatment of complicated urinary tract infections. We report kinetic and crystallographic studies on the inhibition of AmpC, the class C β-lactamase f...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.3390/biom10060899

Authors


More by this author
Institution:
University of Oxford
Division:
MPLS
Department:
Chemistry
Role:
Author
More by this author
Institution:
University of Oxford
Division:
MPLS
Department:
Chemistry
Role:
Author
Expand authors...
More from this funder
Grant:
RLFGD3027 (MR/N002679/1)
Publisher:
MDPI Publisher's website
Journal:
Biomolecules Journal website
Volume:
10
Issue:
6
Article number:
899
Publication date:
2020-06-12
Acceptance date:
2020-05-13
DOI:
ISSN:
2218-273X

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP